Venture capital investments in biotechnology and medical device
companies combined to total $4.7 billion (€4.4bn) in 2002, or 22
per cent of all investing, representing the highest proportion in
seven years, according to the MoneyTree...
Ireland's Elan Corp has inked a deal with Ingenium Pharmaceuticals
of Germany that will see the companies apply Ingenium's functional
genomics technologies to the discovery and development of novel
therapeutics for pain...
British Biotech, once the darling of the UK biotechnology industry
but now suffering the after-effects of a string of major drug
development failures, is having another go at bolstering its
pipeline via a merger with fellow UK company...
A series of new flow cytometry products will soon hit the market
with the announcement yesterday from US companies BD Biosciences
and Molecular Probes that, following a recent license agreement, BD
Biosciences Pharmingen has launched...
SC Biosciences is to be the exclusive distributor of sensitive
tools for drug discovery with the announcement this week that it
will distribute in vivo imaging technology in Japan for US company
Applied Biosystems group, the world's number one maker of
gene-analysing equipment, warned on Tuesday that it would report
lower-than-expected fiscal third-quarter revenue and earnings due
to deteriorating business conditions.
In the second mass spectrometer news of the week, life science
product company Agilent Technologies has introduced an ion trap
mass spectrometer that is approximately 10 times more sensitive
than its predecessor, the company claims.
Drug target validation has become the critical step in maintaining
profitability for the pharmaceutical industry, claims a new report
from market research company Business Communications. Drug
developers must accelerate identification...
A new approach to identifying patterns in gene expression analysis
has been shown to be more effective than the most popular method in
a joint Penn State and University at Buffalo study, write US
scientists this week.
In its first progress report since adopting the EU strategy on life
sciences and biotechnology in 2002, the European Commission
yesterday indicated that the risk of diverging policies in Member
States could seriously hamper the effectiveness...